XBIO · Xenetic Biosciences, Inc.
AI read · Bad for XBIO
The AI's read
The deal hands Santersus shareholders about 85% of the combined company and leaves current Xenetic holders with roughly 15% on a fully diluted basis. That large ownership shift will sharply reduce each existing Xenetic share's claim on the company and requires multiple stockholder approvals while the filing gives little detail about Santersus's business to justify that dilution.